Cyclic adhesion inhibitors
    1.
    发明授权
    Cyclic adhesion inhibitors 有权
    环状粘连抑制剂

    公开(公告)号:US06127335A

    公开(公告)日:2000-10-03

    申请号:US155721

    申请日:1999-04-08

    CPC分类号: C07K7/64 C07K14/75 A61K38/00

    摘要: The invention concerns cyclopeptides of formula (I): Cyclo-(Arg-Gly-Asp-X-Y) in which X is Cha, Nal, Phe, 2-R.sup.1 -Phe, 3-R.sup.1 -Phe, 4-R.sup.1 -Phe, homo-Phe, Phg, Thi, Trp, Tyr or derivatives of Tyr, whereby the OH group can be etherified by alkyl groups containing 1-18 C-atoms and the amino-acid groups given can also be derivatives, R.sup.1 is NH.sub.2, NO.sub.2, I Br, Cl, F, alkyl with 1-18 C-atoms, Ar, Ar--O or.sup.3 H, Y is Gly in which the .alpha. N-atom may be substituted by R.sup.2 and/or the .alpha. C-atom may be substituted by R.sup.3 and/or R.sup.4, with the provision that Gly has at least one of the substituents specified, Ar is phenyl which may be substituted by one or two of groups NH.sub.2, NO.sub.2, I, Br, Cl, F, alkyl with 1-6 C-atoms or .sup.3 H, R.sup.2, R.sup.3 or R.sup.4, independently of each other, are alkyl with 1-18 C-atoms or R.sup.2 and R.sup.3 or R.sup.3 and R.sup.4 together in each case are a branched or unbranched alklyene chain with 3 to 18 C-atoms so that either the .alpha. N-atom or the .alpha. C-atom together with the alkylene chain, or the .alpha. C-atom alone, forms a ring with alkylene chain, whereby, when optically active amino-acid or amino-acid-derivative groups are involved, both the D- and the L-form are included, plus derivatives, in particular the .beta.-ester of aspartic acid or N-guanidine acyl derivatives of arginine or prodrug as well as their physiologically acceptable salts. These compounds act as integrin inhibitors and may be used particularly for the prophylaxis and treatment of circulatory and angiogenic conditions and microbial infections as well as in tumor therapy.

    摘要翻译: PCT No.PCT / EP97 / 01657 Sec。 371日期1999年4月8日 102(e)1999年4月8日PCT PCT 1997年4月2日PCT公布。 公开号WO97 / 38009 日期:1997年10月16日本发明涉及式(I)的环肽:其中X为Cha,Nal,Phe,2-R1-Phe,3-R1-Phe,4- R1-Phe,hom-Phe,Phg,Thi,Trp,Tyr或Tyr的衍生物,其中OH基团可以被含有1-18个C原子的烷基醚化,并且所给出的氨基酸基团也可以是衍生物,R1 是NH 2,NO 2,I Br,Cl,F,具有1-18个C原子的烷基,Ar,Ar-O或3 H,Y是其中αN原子可以被R 2和/或αC- 原子可以被R 3和/或R 4取代,条件是Gly具有至少一个指定的取代基,Ar是可被一个或两个NH 2,NO 2,I,Br,Cl,F, 具有1-6个C原子的烷基或3H,R 2,R 3或R 4彼此独立地是具有1-18个碳原子的烷基或者R 2,R 3或R 3和R 4在每种情况下一起是支链或非支链烷基链 具有3至18个C原子,使得αN原子或αC原子与亚烷基链一起,或者 单独的αC原子形成具有亚烷基链的环,由此当涉及光学活性氨基酸或氨基酸衍生物基团时,包括D-和L-形式,加上衍生物,特别是β 的天冬氨酸或精氨酸或前药的N-胍酰基衍生物及其生理上可接受的盐。 这些化合物作为整合素抑制剂起作用,可用于预防和治疗循环和血管生成病症和微生物感染以及肿瘤治疗。

    Inhibitors for urokinase receptor
    2.
    发明授权
    Inhibitors for urokinase receptor 失效
    尿激酶受体抑制剂

    公开(公告)号:US06528619B1

    公开(公告)日:2003-03-04

    申请号:US09402641

    申请日:2000-01-10

    IPC分类号: C07K708

    CPC分类号: C12N9/6462 C12Y304/21073

    摘要: The present invention provides peptides as inhibitors of the binding of urokinase to the urokinase receptor. The peptides have the general structural formula (I): X1-[X2]n-X3-X4-K-Y-F-X5-X6-I-X7-W-[X8]m  (I) in which X1, X2, X3, X4, X5, X6, X7 and X8 each denote an aminocarboxylic acid, n and m are each independently 0 or 1, K denotes an aminocarboxylic acid with a lysine side chain, Y denotes an aminocarboxylic acid with a tyrosine side chain, F denotes an aminocarboxylic acid with a phenyl-alanine side chain, I denotes an aminocarboxylic acid with an isoleucine side chain, W denotes an aminocarboxylic acid with a tryptophan side chain, and the monomeric building blocks are linked by —CONR1— or —NR1CO— bonds where R1 in each case independently denotes hydrogen, methyl or ethyl, and pharmaceutically compatible salts and derivatives thereof.

    摘要翻译: 本发明提供肽作为尿激酶与尿激酶受体结合的抑制剂。 肽具有通式结构式(I):其中X 1,X 2,X 3,X 4,X 5,X 6,X 7和X 8各自表示氨基羧酸,n和m各自独立地为0或1,K表示氨基羧酸, 赖氨酸侧链,Y表示具有酪氨酸侧链的氨基羧酸,F表示具有苯基 - 丙氨酸侧链的氨基羧酸,I表示具有异亮氨酸侧链的氨基羧酸,W表示具有色氨酸侧链的氨基羧酸, 并且单体结构单元通过-CONR1-或-NR1CO-键连接,其中R 1在每种情况下独立地表示氢,甲基或乙基,以及其药学上相容的盐和衍生物。